JAMES B. BREITMEYER - 03 Jan 2023 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Role
Chief Executive Officer, Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
03 Jan 2023
Net transactions value
-$29,700
Form type
4
Filing time
05 Jan 2023, 17:00:49 UTC
Previous filing
01 Aug 2022
Next filing
24 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCT Common Stock Tax liability $28,349 -27,793 -4.9% $1.02 541,981 03 Jan 2023 Direct F1
transaction ONCT Common Stock Tax liability $1,352 -1,325 -5.2% $1.02 23,918 03 Jan 2023 By Spouse F1
holding ONCT Common Stock 46,544 03 Jan 2023 By Family Trust
holding ONCT Common Stock 733 03 Jan 2023 By Child
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units.